Note: Presentation Cancelled

Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals

Title: Silencing MMP7 expression with a lung-targeted RNAi molecule limits fibrosis and preserves pulmonary function in bleomycin-injured rats
Presenter: Erik Bush, Ph.D., Group Vice President, Biology, Arrowhead Pharmaceuticals

Title: Effects of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 on Viral Markers of Chronic Hepatitis B: Results From the REEF-1 Study
Presenter: Man-Fung Yuen, Department of Medicine & State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong

Title: Understanding the Dynamics of HBsAg Decline Through Model-informed Drug Development (MIDD) of siRNA and CAM-N for the Treatment of Chronic Hepatitis B (CHB) Virus Infection
Presenter: Huybrecht T’jollyn, Janssen Research & Development

Title: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study
Presenter: Kosh Agarwal, Institute of Liver Studies, King’s College Hospital

Title: Reduction of Intra-hepatic Z-AAT Synthesis by Fazirsiran Decreases Globule Burden and Improves Histological Measures of Liver Disease in Adults with Alpha-1 Antitrypsin Deficiency
Presenter: Pavel Strnad, Department of Internal Medicine III, University Hospital, Rwth Aachen